{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:03:32Z","timestamp":1759104212803,"version":"3.44.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"MSWA Post-Doctoral Research Fellowship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jneuroim.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T13:02:35Z","timestamp":1536930155000},"page":"76-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia"],"prefix":"10.1016","volume":"324","author":[{"given":"Marzena J.","family":"Fabis-Pedrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Bundell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee-Keong","family":"Wee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McLean-Tooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank L.","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jneuroim.2018.09.006_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2013.06.009","article-title":"NMO spectrum disorders comprise the major portion of CNS inflammatory diseases in Thai patients: a cross sectional study","volume":"3","author":"Apiwattanakul","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2018.09.006_bb0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2012.07.014","article-title":"Diagnostic utility of NMO\/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients","volume":"320","author":"Apiwattanakul","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.09.006_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-0404.2008.01002.x","article-title":"Neuromyelitis optica: a distinct demyelinating disease of the central nervous system","volume":"118","author":"Argyriou","year":"2008","journal-title":"Acta Neurol. Scand."},{"issue":"18","key":"10.1016\/j.jneuroim.2018.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.09.006_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-13-33","article-title":"Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study","volume":"13","author":"Asgari","year":"2013","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2018.09.006_bb0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1352458508101935","article-title":"Neuromyelitis optica in Brazil: a study on clinical and prognostic factors","volume":"15","author":"Bichuetti","year":"2009","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.jneuroim.2018.09.006_bb0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"S4","key":"10.1016\/j.jneuroim.2018.09.006_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/imj.70_13197","article-title":"ASCIA-P70: is testing for AQP4 antibodies in CSF and serum more sensitive than serum alone?","volume":"46","author":"Bundell","year":"2016","journal-title":"Intern. Med. J."},{"issue":"7","key":"10.1016\/j.jneuroim.2018.09.006_bb0045","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/1352458509104585","article-title":"Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies","volume":"15","author":"Cabrera-Gomez","year":"2009","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jneuroim.2018.09.006_bb0050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: a multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jneuroim.2018.09.006_bb0055","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archneurol.2011.127","article-title":"A benign form of neuromyelitis optica: does it exist?","volume":"68","author":"Collongues","year":"2011","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2018.09.006_bb0060","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1352458509106851","article-title":"Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients","volume":"15","author":"Fazio","year":"2009","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.09.006_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.09.006_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000011","article-title":"AQP4 autoantibody assay performance in clinical laboratory service","volume":"1","author":"Fryer","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"14","key":"10.1016\/j.jneuroim.2018.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.0b013e3182a6cc23","article-title":"AQP4 antibody serostatus: is its luster being lost in the management and pathogenesis of NMO?","volume":"81","author":"Fujihara","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jneuroim.2018.09.006_bb0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"issue":"13","key":"10.1016\/j.jneuroim.2018.09.006_bb0085","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.wnl.0000256822.01222.bd","article-title":"NMO-IgG in the diagnosis of neuromyelitis optica","volume":"68","author":"Jarius","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.09.006_bb0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2018.09.006_bb0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"14","key":"10.1016\/j.jneuroim.2018.09.006_bb0100","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jneuroim.2018.09.006_bb0105","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim","year":"2010","journal-title":"Mult. Scler."},{"issue":"15","key":"10.1016\/j.jneuroim.2018.09.006_bb0110","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.0b013e31824f8069","article-title":"Clinical spectrum of CNS aquaporin-4 autoimmunity","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jneuroim.2018.09.006_bb0115","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/1352458512472748","article-title":"Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders","volume":"19","author":"Kim","year":"2013","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.09.006_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pathophys.2010.04.008","article-title":"Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis","volume":"18","author":"Kira","year":"2011","journal-title":"Pathophysiology"},{"issue":"9451","key":"10.1016\/j.jneuroim.2018.09.006_bb0125","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2018.09.006_bb0130","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"24","key":"10.1016\/j.jneuroim.2018.09.006_bb0135","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.09.006_bb0140","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/brain\/awm027","article-title":"Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese","volume":"130","author":"Matsuoka","year":"2007","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.jneuroim.2018.09.006_bb0145","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2018.09.006_bb0150","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jneuroim.2018.09.006_bb0155","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp.2005.080390","article-title":"Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG","volume":"77","author":"Nakashima","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jneuroim.2018.09.006_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","article-title":"Demyelinating diseases in Asia","volume":"29","author":"Ochi","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.09.006_bb0165","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4103\/0972-2327.120474","article-title":"Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: experience from the Mangalore demyelinating disease registry","volume":"16","author":"Pandit","year":"2013","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.09.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040133","article-title":"Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica","volume":"4","author":"Paul","year":"2007","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.jneuroim.2018.09.006_bb0175","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2014.1581","article-title":"Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis","volume":"71","author":"Pittock","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2018.09.006_bb0180","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2018.09.006_bb0185","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1352458509355463","article-title":"Low level of systemic autoimmunity in Western Australian multiple sclerosis patients","volume":"16","author":"Qiu","year":"2010","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jneuroim.2018.09.006_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/jnnp.2009.172973","article-title":"Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database","volume":"81","author":"Qiu","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jneuroim.2018.09.006_bb0195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.24208","article-title":"Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks","volume":"76","author":"Sato","year":"2014","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2018.09.006_bb0200","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2018.09.006_bb0205","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1212\/WNL.0b013e31822c61b1","article-title":"AQP4 antibody-positive Thai cases: clinical features and diagnostic problems","volume":"77","author":"Siritho","year":"2011","journal-title":"Neurology"},{"issue":"Pt 5","key":"10.1016\/j.jneuroim.2018.09.006_bb0210","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jneuroim.2018.09.006_bb0215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2018.09.006_bb0220","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2018.09.006_bb0225","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2018.09.006_bb0230","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jneuroim.2018.09.006_bb0235","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2018.09.006_bb0240","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818303205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818303205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:33:15Z","timestamp":1759048395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572818303205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":48,"alternative-id":["S0165572818303205"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.09.006","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}